Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Radboud start fase I/II-studie naar COVID-19-vaccin
mrt 2021 | Vaccinatie, Virale infecties